Charles River recently announced the expansion of its plasmid DNA and viral vector development and manufacturing capabilities in Europe; it says the move is to support the growing need of customers and to safeguard future supply.
Cobra Biologics, the gene therapy division of the Charles River owned Cognate BioServices, and Sweden's CombiGene recently announced the successful production and quality assurance of the plasmids to be used in the GMP production of the gene therapy,...
Cobra and Symbiosis announce the completion of their collaboration on viral vector development and manufacturing, supported by £1.9m Innovate UK grant.